- Home
- GMAB
GMAB
Genmab A/S ADS
as 05-09-2025 4:00pm EST
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $39.17 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 17.68 | EPS Growth: | 85.27 |
| 52 Week Low/High: | $17.24 - $30.41 | Next Earning Date: | 05-08-2025 |
| Revenue: | $3,135,137,804 | Revenue Growth: | 51.92% |
| Revenue Growth (this year): | 13.38% | Revenue Growth (next year): | 15.36% |
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
MT Newswires
3 days ago
Genmab Q1 Earnings, Revenue Increase
GlobeNewswire
3 days ago
Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire
7 days ago
Transactions in Connection with Share Buy-back Program
MT Newswires
10 days ago
Sector Update: Health Care Stocks Rise Premarket Friday
MT Newswires
10 days ago
Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy
Business Wire
10 days ago
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Insider Monkey
11 days ago
Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?
Compare GMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.